Selective loss of nucleoside carrier expression in rat hepatocarcinomas.
Evidence that hepatoma cell lines show differential expression of concentrative nucleoside transporters (CNT1 and CNT2) prompted us to study the transporter proteins in 2 models of hepatocarcinogenesis, the chemically induced Solt and Farber model and the albumin-SV40 large T antigen (Alb-SV40) transgenic rat. CNT1 expression was lower in tumor biopsy specimens from Alb-SV40 rat livers than in normal tissue. Immunocytochemistry revealed that the CNT1 protein was indeed absent in the tumor lesions. CNT1 was also absent in a cell line, L25, derived from the Alb-SV40 transgenic rat liver tumors, whereas another cell line, L37, derived from the normal-appearing parenchyma, retained the expression of both carrier isoforms. The protein expression correlated with the nucleoside transport properties of these cell lines. Moreover, although CNT2 expression was highly dependent on the growth characteristics of the 2 cell lines, as was CNT1 (albeit to a lower extent) in L37 cells, it was not expressed in L25 cells at any stage of cell growth. In contrast to the transgenic model of hepatocarcinogenesis, in the chemically induced tumors the expression of CNT2 was lower, although still detectable. In summary, these data indicate that hepatocarcinogenesis leads to a selective loss or diminished expression of nucleoside carrier isoforms, a feature that may be relevant to our understanding of the molecular basis of the bioavailability of those drugs that are nucleoside derivatives and may be substrates of these carriers. The transport properties and isoform-expression profile of the L25 and L37 cell lines make them suitable hepatocyte culture models with which to study nucleoside transport processes and drug sensitivity.
Dragan
Y
Y
McArdle Laboratory for Cancer Research, Department of Oncology, School of Medicine, University of Wisconsin, Madison, WI, USA.
Valdés
R
R
Gomez-Angelats
M
M
Felipe
A
A
Javier Casado
F
F
Pitot
H
H
Pastor-Anglada
M
M
D000818:Animals; D030801:Animals, Genetically Modified; D006528:Carcinoma, Hepatocellular / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D002352:Carrier Proteins / Q000032:analysis* / Q000235:genetics; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase / Q000235:genetics; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000235:genetics; D008113:Liver Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D026901:Membrane Transport Proteins; D009705:Nucleosides / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344; D014407:Tumor Cells, Cultured
D002352:Carrier Proteins; D007527:Isoenzymes; D026901:Membrane Transport Proteins; D009705:Nucleosides; C065171:cif nucleoside transporter; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; C496558:Gstp1 protein, rat